SEARCH

SEARCH BY CITATION

References

  • Badri M, Cleary S, Maartens G et al. (2006a) When to initiate highly active antiretroviral therapy in sub-Saharan Africa? A South African cost-effectiveness study. Antiviral Therapy 11, 6372.
  • Badri M, Maartens G, Mandalia S et al. (2006b) Cost-effectiveness of highly active antiretroviral therapy in South Africa. PLoS Medicine 3, e4.
  • Bagchi S, Kempf MC, Westfall AO, Maherya A, Willig J & Saag MS (2007) Can routine clinical markers be used longitudinally to monitor antiretroviral therapy success in resource-limited settings? Clinical Infectious Diseases 44, 135138.
  • Bekker LG, Myer L, Orrell C, Lawn S & Wood R (2006) Rapid scale-up of a community-based HIV treatment service: programme performance over 3 consecutive years in Guguletu, South Africa. South African Medical Journal 96, 315320.
  • Braitstein P, Brinkhof MW, Dabis F et al. (2006) Mortality of HIV-1-infected patients in the first year of antiretroviral therapy: comparison between low-income and high-income countries. Lancet 367, 817824.
  • Cleary SM, McIntyre D & Boulle AM (2006) The cost-effectiveness of Antiretroviral Treatment in Khayelitsha, South Africa - a primary data analysis. Cost Effectiveness and Resource Allocation 4, 20.
  • Coetzee D, Hildebrand K, Boulle A et al. (2004) Outcomes after two years of providing antiretroviral treatment in Khayelitsha, South Africa. AIDS 18, 887895.
  • Etard JF, Ndiaye I, Thierry-Mieg M et al. (2006) Mortality and causes of death in adults receiving highly active antiretroviral therapy in Senegal: a 7-year cohort study. AIDS 20, 11811189.
  • Goldie SJ, Yazdanpanah Y, Losina E et al. (2006) Cost-effectiveness of HIV treatment in resource-poor settings – the case of Cote d’Ivoire. New England Journal of Medicine 355, 11411153.
  • Grabar S, Le Moing V, Goujard C et al. (2005) Response to highly active antiretroviral therapy at 6 months and long-term disease progression in HIV-1 infection. Journal of Acquired Immune Deficiency Syndromes 39, 284292.
  • Harling G & Wood R (2007) The evolving cost of HIV in South Africa: changes in health care cost with duration on antiretroviral therapy for public sector patients. Journal of Acquired Immune Deficiency Syndromes 45, 348354.
  • Hassan F (2007) Joint Civil Society Monitoring Forum: ARV Numbers. Joint Civil Society Monitoring Forum, Johannesburg, South Africa.
  • Ivers LC, Kendrick D & Doucette K (2005) Efficacy of antiretroviral therapy programmes in resource-poor settings: a meta-analysis of the published literature. Clinical Infectious Diseases 41, 217224.
  • Kabugo C, Bahendeka S, Mwebaze R et al. (2005) Long-term experience providing antiretroviral drugs in a fee-for-service HIV clinic in Uganda: evidence of extended virologic and CD4+ cell count responses. Journal of Acquired Immune Deficiency Syndromes 38, 578583.
  • Rosen S & Long L (2006) How Much Does It Cost to Provide Antiretroviral Therapy for HIV/AIDS in Africa? Health and Development Discussion Paper 9. Boston University Center for International Health and Development, Boston, MA.
  • Rosen S, Ketlhapile M, Sanne I & Bachman DeSilva M (2007) Costs to patients of obtaining treatment for HIV/AIDS in South Africa. South African Medical Journal 97, 524529.
  • Shisana O, Rehle T, Simbayi LC et al. (2005) South African National HIV Prevalence, HIV Incidence, Behaviour, and Communication Survey, 2005. HSRC Press, Cape Town, South Africa.
  • South Africa Department of Health (2004) National Antiretroviral Treatment Guidelines. South African National Department of Health, Pretoria, South Africa.
  • South African Department of Health (2003) Operational Plan for Comprehensive HIV and AIDS Care, Management, and Treatment for South Africa. South African National Department of Health, Pretoria, South Africa.
  • Sow PS, Otieno LF, Bissagnene E et al. (2006) Implementation of an antiretroviral access programme for HIV-1-infected individuals in resource-limited settings: clinical results from 4 African countries. Journal of Acquired Immune Deficiency Syndromes 44(Suppl. 3), 262267.
  • Stringer JS, Zulu I, Levy J et al. (2006) Rapid scale-up of antiretroviral therapy at primary care sites in Zambia: feasibility and early outcomes. JAMA 296, 782793.
  • WHO (2006) Progress on Global Access to HIV Antiretroviral Therapy: A Report on “3 by 5” and Beyond, March 2006. World Health Organization, Geneva.
  • Wools-Kaloustian K, Kimaiyo S, Diero L et al. (2006) Viability and effectiveness of large-scale HIV treatment initiatives in sub-Saharan Africa: experience from western Kenya. AIDS 20, 4148.